Rocket Pharmaceuticals (NASDAQ:RCKT) is a biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases. The company's pipeline includes projects aimed at addressing genetic disorders through cutting-edge treatments that target the underlying causes of these conditions. With a commitment to innovation and improving patient outcomes, Rocket Pharmaceuticals is dedicated to advancing its gene therapy projects from preclinical stages through clinical trials, with the goal of bringing new, transformative treatments to market. The company operates a patient-centric approach, collaborating with researchers and healthcare professionals to ensure its therapies meet the unmet needs of those affected by rare genetic diseases.